Back to search results

Observational Study of Exosomes in Pancreatic Cancer

This study aims to understand how tiny messengers called exosomes, found in blood and tissue, are involved in pancreatic cancer. Researchers will collect blood and tissue samples from patients undergoing surgery for pancreatic cancer or other non-cancerous pancreatic conditions. By comparing these samples, they hope to establish "normal" exosome levels and see if exosome activity is linked to how the disease progresses or returns. This information will help guide future research. The study is looking to enroll 181 participants aged 18 and older who are having specific pancreatic surgeries.

Study design
This is an observational study planning to enroll 181 participants. It compares samples from patients with pancreatic cancer to those with non-cancerous pancreatic disease.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, successful isolation of exosomes, is measured at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02393703

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Recruiting
Not specifiedAges 18+Observational
Memorial Sloan Kettering Cancer Center
~181 participants
Updated 2026-02-09 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
successful isolation of exosomes
Measured over 1 year

Conditions

Pancreatic Cancer
Benign Pancreatic Disease

Explore related trials

Benign Pancreatic DiseasePancreatic Carcinoma

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • William Jarnagin, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

William Jarnagin, MD
212-639-7601
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All patients ≥ 18 years of age undergoing pancreaticoduodenectomy, partial or complete pancreatectomy, and duodenal ampullectomy for presumed ductal adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN) or pancreatic neuroendocrine tumors, without an invasive component; or other benign pancreatic disease will be eligible.
For third part of the study, recipient of neoadjuvant chemotherapy will be accrued to the neoadjuvant group (25 patients). Patients without neoadjuvant chemotherapy will be accrued to the non-neoadjuvant group (25 patients).

Exclusion

The presence of metastatic disease or disease that precludes resection
For first and second part of the study, receipt of neoadjuvant chemotherapy or radiation for the index cancer within 6 months of being enrolled in the study
For third part of the study, receipt of neoadjuvant radiation for the index cancer within 6 months of being enrolled in the study
INR \>2
Known clotting factor deficiency or hypercoagulable state
Any patient with the need or anticipated need for full anti-coagulation during hospitalization for the resection.
Receipt of antiplatelet agents (other than aspirin) in the preceding week prior to resection.
IPMN or pancreatic neuroendocrine tumors by radiographic imaging with high suspicion for invasive component Additionally, if at the discretion of the operating surgeon, blood collection would lead to undue morbidity, the patient will be excluded and replaced

What this trial measures

  • successful isolation of exosomes1 year

    isolation of at least 100,000 microvesicles is needed for exosomes purification for down stream applications such as proteomics and RNA sequencing.